Shubham Maurya

Dr. Shubham Maurya

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2026 in JCI Insight
Verified
Journal Article
Open access
PDF file
DMDavid J. Mathew
David J. Mathew
SMShubham Maurya
Shubham Maurya
JHJulian Ho
Julian Ho
ILIzhar Livne-Bar
Izhar Livne-Bar
DCDarren Chan
Darren Chan
JSJeremy M. Sivak
Jeremy M. Sivak
Synthetic prostaglandin analogs, such as latanoprost, are first-line treatments to reduce intraocular pressure (IOP) in the management of glaucoma, treating millions of patients daily. Glaucoma is a leading cause of blindness, characterized by progressive optic neuropathy, with elevated IOP being the sole modifiable risk factor. Despite this importance, the underlying latanoprost mechanism of action is still not well defined, being associated with both acute and long-term activities, and a growing list of ocular side effects. Prostaglandins are eicosanoid lipid mediators. Yet, there has not been a comprehensive assessment of small lipid mediators in glaucomatous eyes. Here, we performed a lipidomic screen of aqueous humor sampled from patients with glaucoma and healthy control eyes. The resulting signature was surprisingly focused on significantly elevated levels of arachidonic acid (AA) and its derivative, the antiinflammatory and cytoprotective mediator, lipoxin A 4 (LXA 4 ), in glaucomatous eyes. Subsequent experiments revealed that this response was drug induced, due to latanoprost actions on trabecular meshwork cells, rather than a consequence of elevated IOP. We demonstrate that increased LXA 4 inhibited proinflammatory cues and promoted TGF-β production in the anterior chamber. In concert, an autocrine prostaglandin circuit mediated canonical rapid IOP lowering. This work reveals parallel mechanisms underlying acute and long-term latanoprost activities during glaucoma treatment.

18 March 2026 in Progress in Retinal and Eye Research
Verified
Journal Article
Open access
EWEmily Lauren Ward
Emily Lauren Ward
SKShruthi Karnam
Shruthi Karnam
ACAmogh Changavi
Amogh Changavi
MKMatangi Kumar
Matangi Kumar
SMShubham Maurya
Shubham Maurya
JFJohn G. Flanagan
John G. Flanagan
Prostaglandin D2 (PGD2), PGE2, and other prostanoids play important roles in retinal and optic nerve (ON) health and disease, including neovascularization, neuroinflammation, and neurodegeneration. We reviewed the synthesis, expression, regulation, mechanisms, and functions of the principal prostanoids (PGF2α, PGI2, TXA2, PGE2, and PGD2) in the eye. Prostanoids can be difficult to study in-vivo or ex-vivo because they are small, unstable molecules. To address this, we incorporated lipidomics data clarifying the prostanoids present in the mouse retina and ON, and mined single-cell transcriptomic atlases of the human and mouse posterior eye to map prostanoid pathway expression across cell types. We identified species-, tissue-, and region-specific differences in prostanoid synthase and receptor expression. The PGF2α receptor (FP) was detected in mouse but not human retinal ganglion cells (RGCs). TXA2 synthase was present in ON but not retinal glia. DP2 and EP1 were enriched in microglia and astrocytes of the retrolaminar ON, but not the ON head. Analysis of mouse RGC degeneration datasets revealed dynamic regulation of prostanoid pathways in glia and RGCs. During early degeneration, macroglia upregulated PGD2 synthase (L-PGDS), while microglia upregulated the PGE2 receptor EP4. Glia downregulated intrinsic COX-1 pathways, yet we did not observe induction of COX-2. Topical NSAID treatment exacerbates RGC damage following mouse ocular hypertension, underscoring the need to clarify COX-1/2 roles in the eye. In conclusion, intrinsic prostanoid networks support retinal and ON homeostasis and are dynamically regulated in disease, representing cell-specific, receptor, and disease stage therapeutic targets, including potential RGC protection.